Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Evolent Health reported Q3 2026 revenue of $725.4 million, a significant increase from $479.5 million in the prior year, driven by strong demand for complex specialty care solutions and oncology launches. The company also announced a four-year renewal of its largest Surgical Management contract and two new oncology service expansions with national payers.
“As health plan customers seek to balance affordability with patient and doctor experience, they continue to turn to Evolent by renewing agreements and in many cases, expanding the work they do with us. That growth and demand from existing clients, as well as strong execution in our 2026 oncology launches, continue to drive strong performance in 2026. Looking ahead, I believe our innovative AI platform and our oncology solution will drive growth and margin expansion for Evolent in the quarters to come.”
Seth Blackley, Co-Founder and Chief Executive Officer of Evolent
REGENXBIO reported Q3 2026 financial results, highlighting progress toward a BLA submission for its Duchenne muscular dystrophy gene therapy RGX-202 in Q1 2027. The company also expects topline pivotal data for its wet AMD candidate sura-vec in Q4 2026, with global regulatory submissions planned for 2027.
“We are continuing to build momentum as we prepare to launch potential first- or best-in-class gene therapies in 2027 and 2028. With topline pivotal data expected this quarter, sura-vec has the potential to transform the treatment paradigm for a broad spectrum of patients with wet AMD. We also remain on track for the RGX-202 BLA submission early next year as we work toward delivering this important therapy to Duchenne patients as quickly as possible. We remain focused on executing these near-term milestones and leveraging our fully integrated capabilities to deliver meaningful new treatment options for patients.”
Curran Simpson, President and Chief Executive Officer of REGENXBIO
Vistance Networks reported Q3 2026 net sales of $319.7 million and GAAP income from continuing operations of $54.7 million. Alongside the results, the company announced a new $100 million stock repurchase program and revised its full-year adjusted EBITDA guidance downward due to customer demand shifting into 2027.
“During the third quarter, we continued to make progress across our Vistance Networks business, supported by ongoing DOCSIS 4.0 deployments and adoption of our next-generation intelligent amplifiers. While memory chip pressures and customer deployment timing continue to impact near-term performance, we remain confident in the long-term demand for our products and opportunities to expand our portfolio. We are also pleased with the significant value we have returned to shareholders following the divestitures of our CCS and RUCKUS businesses. Including our recently announced $1.50 per share special distribution, we will have distributed $16.50 per share in 2026. As of October 30, 2026, we repurchased $225 million of stock under our existing stock repurchase programs. With a strong, debt-free balance sheet, we are well positioned to continue investing in our business and creating additional value.”
Chuck Treadway, President and Chief Executive Officer
“Aurora Networks delivered $320 million of revenue and $57 million of Adjusted EBITDA in the third quarter. This was generally aligned with our expectations as memory chip pricing and stranded costs were more than offset by a lower variable compensation. Looking ahead, we are revising our full-year adjusted EBITDA guidance to $180 million to $200 million, primarily resulting from customer demand being pushed out into 2027. We remain confident in the underlying demand for our products and are focused on managing costs, maintaining financial flexibility and positioning the business to capitalize on longer-term network upgrade opportunities.”
LCI Industries reported third quarter 2026 net sales of $992.5 million and net income of $50.1 million, with growth in adjacent industries and aftermarket sales helping to offset lower RV OEM demand. The company highlighted operating margin expansion and progress toward its pending all-stock merger with Patrick Industries, which is expected to close in the first half of 2027.
Term
Q3 2026
“Our third-quarter results reflect continued progress in improving profitability in a soft outdoor recreation market. Margin expansion and 6% growth in product content per unit contributed to our performance and position us to achieve our updated full-year outlook.”
Johnny Sirpilla, Interim Chief Executive Officer
“Our new product pipeline and the repair and replacement needs of the installed RV base provide opportunities to serve customers even as demand for new units remains constrained. We are also advancing toward the proposed merger with Patrick Industries, which we continue to expect to close in the first half of 2027.”
OpenText reported its first quarter fiscal year 2027 results, featuring total revenues of $1.237 billion and core cloud revenue growth of 11% year-over-year. The company also declared a quarterly cash dividend of $0.28 per share and highlighted a $1.0 billion debt refinancing completed after the quarter's end.
“Our first quarter reflects the strength of our core portfolio and the value we deliver for clients. As clients move to AI, they need trusted context and connected data for outcomes they can rely on. With Aviator AI agents infused across our core portfolio and a go-to-market model built around our clients' success, we are supporting them at every step of their AI journey.”
Ayman Antoun, OpenText CEO
“OpenText delivered strong performance in the first quarter of Fiscal 2027, supported by continued financial and operational discipline. Following the quarter, we completed a $1.0 billion debt refinancing and paid down $300 million in debt through a successfully completed tender offer, providing the Company with greater financial flexibility. The durability of our operating model enables us to execute our capital allocation priorities through the remainder of Fiscal 2027.”
Tecnoglass reported record third-quarter revenue of $310.6 million, a 19.2% year-over-year increase driven by strong growth in multi-family and commercial business. Net income was $22.8 million, though margins were pressured by elevated aluminum costs and a strong Colombian Peso. The company's backlog reached a record $1.43 billion, providing strong visibility into 2027.
Term
Q3 2026
“We were pleased to deliver record revenues in the third quarter, up 19% year-over-year, led by 31% growth in our multi-family and commercial business. Single-family residential revenues grew 17% year-over-year excluding the previously disclosed pre-buy activity in the second quarter, reflecting continued market share gains as we expand outside of Florida.”
José Manuel Daes, Chief Executive Officer of Tecnoglass
“Our backlog reached another record of $1.43 billion, extending our track record of sequential growth since 2021 and reflecting consistent execution on a growing pipeline of multi-family and commercial projects.”
Christian Daes, Chief Operating Officer of Tecnoglass
Cooper-Standard Holdings reported Q3 2026 sales of $708.6 million, a 1.9% increase year-over-year despite a decline in global light vehicle production. The company posted a net loss of $20.4 million, primarily driven by $19.2 million in restructuring charges, while securing $148.8 million in net new business awards during the quarter.
Term
Q3 2026
“We are continuing to leverage our strong customer relationships to book new business awards at a record pace, with overall average contribution margins consistent with our longer-term strategic plans and targets.”
Jeffrey Edwards, chairman and CEO, Cooper Standard
“While headwinds from commodity prices and general inflation remained greater than we had expected in the third quarter, we are working with our customers to refine our commercial agreements and accelerate the timing of cost recoveries wherever possible.”
Jeffrey Edwards, chairman and CEO, Cooper Standard
Wendy's reported third-quarter 2026 results with revenues of $547.0 million and net income of $15.1 million. The company launched 'Dave’s Way,' a multi-year strategy focused on growing customer traffic and market share, and signed a letter of intent to acquire up to 163 restaurants from Meritage Hospitality Group.
Term
Q3 2026
“Dave’s Way brings our areas of focus together in one integrated strategy with a clear objective: growing customer traffic and market share while strengthening restaurant profitability. While there is significant work ahead, I’m pleased with our early progress, including testing enhancements to our menu, improving marketing execution and accelerating our digital business.”
Bob Wright, President and Chief Executive Officer
“We have evaluated the investment needs of Dave’s Way and are confident we have the financial capacity to execute the strategy. With approximately $413 million in cash and $174 million of free cash flow year-to-date, we are well positioned to invest in our Dave’s Way strategy.”
Steve Cirulis, Chief Financial Officer and Chief Strategy Officer
1stdibs.com reported Q3 2026 financial results with net revenue of $23.1 million, up 5% year-over-year, and its fourth consecutive quarter of positive Adjusted EBITDA. The company also announced a leadership transition where CEO David Rosenblatt will become Executive Chairperson on January 1, 2027, succeeded by current CPO/CMO Bradford Shellhammer. Additionally, the Board authorized a new $5.0 million share repurchase program.
Term
Q3 2026
“The third quarter was another quarter of product-driven improvement in our operating metrics. Orders grew year over year for the first time since the fourth quarter of 2024, and GMV grew 4% despite continued softness in the high-end furniture market. We believe this performance reflects share gains as our product improvements reach more buyers. We see a large opportunity ahead, and we are focused on capturing it.”
David Rosenblatt, Chief Executive Officer of 1stDibs
“We delivered our fourth consecutive quarter of positive Adjusted EBITDA in the third quarter. We remain focused on expense discipline while investing in the product and engineering work behind our roadmap.”
Ironwood Pharmaceuticals reported Q3 2026 total revenue of $133 million and GAAP net income of $60 million, driven by strong LINZESS U.S. net sales of $325 million. Due to strong performance, the company raised its full-year 2026 LINZESS U.S. net sales guidance to $1.20 - $1.25 billion and total revenue guidance to $485 - $510 million.
Counterparty
AbbVie Inc.
Term
Q3 2026
“Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cash flows. We believe LINZESS is on its way to returning to blockbuster status for 2026 with year-to-date U.S. net sales already surpassing total 2025 U.S. net sales, primarily driven by improved net price and mid-single-digit prescription demand growth.”
Tom McCourt, Ironwood Chief Executive Officer
“In addition to driving strong financial performance, we are ramping up the STARS-2 confirmatory Phase 3 trial of apraglutide in people living with short bowel syndrome with intestinal failure. As we continue to add trial sites in the U.S., all of the planned clinical trial applications have been submitted to international health authorities and are now under review or already approved.”
GPGI, Inc. reported its third quarter 2026 financial results and declared a quarterly cash dividend of $0.0025 per share. The company also provided an investor presentation to accompany the earnings release, detailing its operational performance for the three and nine months ended September 30, 2026.
Zoetis reported third-quarter 2026 revenue of $2.4 billion, a 1% decrease compared to the prior year, driven by macro-driven price sensitivity and competitive pressure in the U.S. companion animal segment. The company narrowed its full-year 2026 revenue guidance and raised its adjusted EPS guidance, citing confidence in its innovation pipeline and livestock growth.
Term
Q3 2026
“Our third-quarter performance was in line with our expectations. Continued pressure in Companion Animal was partially offset by growth in Livestock and Diagnostics, reflecting the breadth of our portfolio.”
Kristin Peck, Chief Executive Officer of Zoetis
“We remain focused on defending our position and directing our resources where they can have the greatest impact. And with the scale, expertise, and pipeline to keep setting the pace of innovation in animal health, we are confident in our ability to create long-term value for customers and shareholders.”
Six Flags Entertainment Corporation reported Q3 2026 net revenues of $1.17 billion, an 11% decrease on a reported basis but a 1.4% increase on a same-park basis. The company recorded a net loss of $366.1 million, which included $687.7 million in non-cash impairment charges. Management highlighted a 36.5% year-to-date increase in operating cash flow and total liquidity of $1.06 billion.
CareCloud reported its most profitable quarter in company history for Q3 2026, achieving record GAAP net income of $4.7 million and record adjusted EBITDA of $9.9 million. Revenue grew 9% year-over-year to $33.7 million, driven by AI-powered healthcare technology and revenue cycle management solutions.
Tripadvisor reported third quarter 2026 financial results, showing an 11% revenue decline to $436.4 million. The company recorded a significant GAAP net loss of $316.9 million, primarily driven by a $369.5 million non-cash goodwill impairment charge. On a non-GAAP basis, the company remained profitable with net income of $43.4 million.
Latigo Biotherapeutics reported Q3 2026 financial results, ending the period with $401 million in cash to fund operations into 2029. The company also announced the appointment of Todd Smith as President and CEO, replacing Nima Farzan, and updated its Phase 3 onzotrigine trial design to include a Percocet comparator arm.
Term
Q3 2026
“With the proceeds from our IPO, we are well-positioned to continue to execute across our development plans for onzotrigine and LTG-321. For onzotrigine, the addition of a Percocet arm to our Phase 3 bunionectomy trial is intended to provide further support for onzotrigine as an opioid-free pain management option in a second surgical model, while also providing data against a commonly used opioid comparator distinct from the one evaluated in our abdominoplasty program.”
Todd N. Smith, president and chief executive officer
Genesis Energy reported Q3 2026 net income of $2.4 million and Adjusted EBITDA of $130.5 million, with results slightly exceeding internal expectations. The company maintained its quarterly distribution at $0.20 per common unit, representing a 21% increase year-over-year, while reporting a bank leverage ratio of 5.03X.
Term
Q3 2026
“Our third quarter results came in modestly ahead of our internal expectations. Our Offshore Pipeline Transportation segment experienced no disruptions of throughput from weather-related producer shut-ins during what is typically the most active part of hurricane season.”
Grant Sims, CEO of Genesis Energy
“Following the significant financing activity in the first half of the year, there is little to report on the balance sheet this quarter. We ended the quarter with no borrowings outstanding under our $900 million senior secured credit facility, approximately $41.5 million of unrestricted cash on hand, no debt maturities until 2029, and a bank-calculated leverage ratio of approximately 5.03x.”
Orion Energy Systems reported Q2 FY2027 revenue of $21.7M, a 9% increase year-over-year, driven by a 40% surge in LED lighting revenue. Despite the revenue growth, the company reported a net loss of $0.8M and reiterated its full-year revenue guidance of $100M-$102M.
Term
Q2 2027
“Orion enters the second half of FY’27 accelerating our initiatives to achieve diversified growth, sustainable margins and market expansion. Whether it’s rapidly growing engagements with major retail chains and logistics leaders, more and more campuses for hyper-scale data-center operators or expanding incumbencies with global automakers, Orion continues on a trajectory to achieve our profitable growth expectations for the current fiscal year.”
Acacia Research reported Q3 2026 total revenue of $54.4 million, an 8% decrease year-over-year primarily due to lower intellectual property license revenue. The company posted a GAAP net loss of $5.6 million but achieved positive Adjusted EBITDA of $3.9 million and ended the quarter with $346.3 million in cash and liquid assets.
“In the third quarter, Acacia generated total revenue of $54.4 million. Our total revenue excluding our Intellectual Property Operations of $54.2 million increased for the third consecutive quarter and was a near record. We also delivered Operated Segment Adjusted EBITDA of $9.1 million and Total Company Adjusted EBITDA of $3.9 million.”
Martin (“MJ”) D. McNulty, Jr., Chief Executive Officer
“We ended the quarter with approximately $346.3 million, or $3.55 per share, in cash, equity securities and loans receivable, up from $3.43 per share last quarter, with no parent-company debt. With an active acquisition pipeline and a flexible investment mandate, we remain focused on compounding long-term intrinsic value per share through disciplined capital allocation.”
Martin (“MJ”) D. McNulty, Jr., Chief Executive Officer
Iovance Biotherapeutics reported record third quarter 2026 total revenue of approximately $122 million, an 80% increase year-over-year, driven by strong demand for its TIL therapy Amtagvi. The company achieved a record gross margin of approximately 60% and reaffirmed its full-year 2026 revenue guidance of $410 million to $420 million.
Term
Q3 2026
“Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand. We remain on track to achieve our full-year 2026 total revenue guidance of $410 to $420 million and recently marked the tremendous milestone of more than 1,000 commercially treated Amtagvi patients.”
Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President
WW International reported Q3 2026 revenue of $152.9 million, driven by 48% year-over-year growth in Clinical Subscription Revenue. The company achieved a net income of $15.1 million and narrowed its full-year 2026 revenue guidance to a range of $625 million to $630 million.
Term
Q3 2026
“Since joining Weight Watchers on October 1, I made it my priority to listen to our members, coaches, clinicians, registered dietitians, and colleagues. Through these conversations, two core truths emerged: weight loss is personal, and the support people need changes along the way.”
Stephen Bye, President and Chief Executive Officer
“We remained focused on strengthening our two higher-value product offerings and proactively calibrating our spend across our portfolio. That approach helped drive sustained progress in these offerings with four quarters of quarter-over-quarter growth in Core+ subscribers, and the largest year-over-year Clinical Subscription Revenue growth percentage in any quarter of 2026 to date.”
Evergy reported third quarter 2026 GAAP EPS of $2.59 and adjusted EPS of $2.58, driven by warmer weather and regulated investment recovery. The company raised its full-year 2026 adjusted EPS guidance to a range of $4.35 to $4.50 and declared a quarterly dividend of $0.7225 per share.
“We finished the third quarter with strong execution against our operational and financial targets while also advancing our large customer strategy that we expect will continue to drive affordability benefits for our customers. Generation reliability outperformed despite a stern test from significantly warmer weather and record peak demand for both Evergy and the Southwest Power Pool.”
David Campbell, chairman and chief executive officer
“Given results ahead of expectations driven by strong operational performance and warmer weather, we are increasing our 2026 adjusted EPS guidance range to $4.35 to $4.50 per share from $4.14 to $4.34 per share. We increased our dividend by 4%, which supports our long-term payout ratio target range of 50% to 60%.”
David Campbell, chairman and chief executive officer
Apyx Medical reported Q3 2026 total revenue of $14.0 million, up 9% year-over-year, driven by 17% growth in its Surgical Aesthetics segment. The company narrowed its net loss to $1.8 million and achieved positive Adjusted EBITDA of $0.4 million while initiating the full commercial launch of its power liposuction handpiece for the AYON system.
Term
Q3 2026
“We are pleased to report 17% growth in our Surgical Aesthetics business for the quarter, reflecting continued adoption of AYON and the progress we are making in executing our commercial strategy. Over the past year, we have continued to demonstrate the value AYON offers by providing a full suite of complementary body contouring capabilities in one integrated platform. We are building on that foundation with the broader commercial launch of power liposuction, which has received very positive early feedback from surgeons since it received FDA clearance earlier this year. We estimate that approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON’s appeal.”
Charlie Goodwin, President and Chief Executive Officer
N-able reported third quarter 2026 revenue of $137.5 million, representing 4.9% year-over-year growth, and exceeded its Adjusted EBITDA guidance with $43.6 million. The company also highlighted the repurchase of approximately 10.2 million shares during the quarter, representing about 5% of its outstanding stock.
Term
Q3 2026
“As cyberthreats escalate, we believe every business, no matter its size, deserves enterprise-grade protection. That conviction is translating into real-world impact, with our AI-powered, end-to-end cybersecurity platform protecting over 500,000 businesses worldwide. We delivered another quarter of profitable growth and our priorities moving forward are clear: keep innovating, keep sharpening our go-to-market execution, and give more businesses the resilience to withstand whatever comes next.”
John Pagliuca, N-able president and CEO
“The backdrop for cybersecurity remains positive, and we continue to operate with discipline in pursuit of the opportunity ahead. Our repurchase of approximately 5% of our outstanding shares this quarter reflects our confidence in our approach and the long-term value of N-able.”
Teleflex reported Q3 2026 revenue of $567.8 million, representing 3.0% pro forma adjusted constant currency growth. The company raised its full-year 2026 adjusted EPS guidance to a range of $7.50 to $7.75 and completed $350 million in share repurchases since July 1, 2026.
Term
Q3 2026
“We are pleased with our third quarter performance, which included margin expansion and robust earnings per share growth, even when excluding IEEPA tariff refunds.”
Jason Weidman, Teleflex’s President and Chief Executive Officer
“Our priorities are clear: strengthening our foundation by delivering our transformation, inclusive of the completion of our Strategic Divestitures and the Vascular Intervention integration, accelerating our organizational effectiveness, and elevating our growth profile within a balanced capital allocation framework.”
Jason Weidman, Teleflex’s President and Chief Executive Officer
Amylyx Pharmaceuticals reported third quarter 2026 financial results and provided a business update, highlighting positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia. The company remains on track to submit a New Drug Application (NDA) by the end of 2026 and recently strengthened its balance sheet with approximately $545 million in net proceeds from a public offering.
“The third quarter was a transformational period for Amylyx, as we reported positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, bringing us one step closer to potentially delivering a first ever FDA-approved treatment to people living with PBH.”
Keel Infrastructure reported Q3 2026 financial results, highlighting a strategic shift from Bitcoin mining to HPC/AI infrastructure development. The company reported revenue of $28 million and a net loss from continuing operations of $62 million, primarily driven by a $55 million non-cash unrealized loss on capped calls.
“Power supply is getting scarcer while demand keeps climbing. Keel’s 2027 and 2028 power is further advanced, more secure, and closer to delivery than it was last quarter. With competitive tension high at all three near-term sites, and multiple creditworthy parties at the negotiation table, I have every confidence we will sign the right leases for each site, ones that deliver the most attractive returns for our shareholders.”
Ben Gagnon, CEO
“We remain strongly capitalized, with approximately $780 million of cash liquidity and no current need for debt or equity financing before signing a lease. Capital we deploy ahead of a lease becomes part of our equity contribution to a project's financing, and we examine opportunities to recycle capital on an ongoing basis.”
Shake Shack reported third quarter 2026 financial results with total revenue increasing 15.2% year-over-year to $423.3 million. The company achieved net income of $17.8 million and opened 37 new system-wide locations during the quarter. Same-Shack sales grew 2.5% compared to the prior year period.
1-800-FLOWERS.COM reported fiscal 2027 first quarter revenue of $171.4 million and a net loss from continuing operations of $50.6 million. The company announced a new segment reporting structure (E-Commerce, Wholesale and Other, and BloomNet) and updated its outlook following the sale of PersonalizationMall.com and Things Remembered.
Term
Q1 2027
“During the fiscal first quarter, we began to see signs of progress across our primary websites, with improving net order demand trends and a moderation in the pace of year-over-year declines. While we are still in the early stages of our transformation, these developments are encouraging and suggest that our initiatives are beginning to take hold.”
Adolfo Villagomez, Chief Executive Officer
“Following our announcement last quarter that we were evaluating capital-raising options, we completed the sale of PersonalizationMall.com and Things Remembered during the fiscal second quarter and entered into an agreement to sell our Jacksonville, FL facility. These actions reflect our continued focus on optimizing our capital structure, reducing debt and providing capital to invest in initiatives that improve performance.”
Astec Industries reported Q3 2026 net sales of $352.4 million, a slight increase of 0.7% year-over-year, but posted a net loss of $12.2 million. The company noted that macroeconomic uncertainty and inflationary headwinds impacted margins, leading to a revision of its full-year 2026 Adjusted EBITDA guidance to a lower range of $140 million to $150 million.
Term
Q3 2026
“Third quarter financial results were less than expected as ongoing macroeconomic uncertainty caused a pause in orders earlier in the year by select asphalt plant customers. This, combined with inflationary headwinds, impacted our sales, mix, absorption and margins during the third quarter. Despite this temporary pause and the delayed renewal of the U.S. federal highway bill, underlying demand rebounded in the third quarter as evidenced by our 49.2% growth in backlog.”
Jaco van der Merwe, Chief Executive Officer
“We are revising our full year 2026 Adjusted EBITDA guidance from the previous range of $160 million to $175 million to $140 million to $150 million.”